The abstract is read at the publisher; the summary is JClub's.
Trastuzumab deruxtecan plus pertuzumab in ERBB2-positive metastatic breast cancer is linked to superior progression-free survival in DESTINY-Breast09, supporting FDA approval and reshaping first-line sequencing questions.
- Why it matters: The field is moving beyond the CLEOPATRA induction–maintenance paradigm, but uncertainty remains about which patients need chemotherapy, how long antibody-drug conjugate therapy should continue, and how dual ERBB2 blockade fits.
- What they did: The review synthesizes evolving first-line strategies, including taxane plus trastuzumab and pertuzumab followed by maintenance anti-ERBB2 therapy, and highlights DESTINY-Breast09 (NCT04784715) plus maintenance expansions such as PATINA (NCT02947685) and HER2CLIMB-05 (NCT05132582).
- The result: The emerging approach is increasingly individualized to balance efficacy, toxicity, and preferences, while biomarker tools like HER2DX and circulating tumor DNA remain investigational for optimizing selection, duration, and sequencing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.